Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 774.05B |
| Revenue (ttm) | 47.38B |
| Net Income (ttm) | 14.68B |
| Shares Out | n/a |
| EPS (ttm) | 16.30 |
| PE Ratio | 52.72 |
| Forward PE | 34.08 |
| Dividend | 5.01 (0.58%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | n/a |
| Average Volume | 39 |
| Open | n/a |
| Previous Close | 870.00 |
| Day's Range | n/a |
| 52-Week Range | 538.08 - 880.00 |
| Beta | 0.33 |
| RSI | 73.05 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
S&P 500 Gains and Losses Today: Intel Soars Amid Apple Deal Rumors; Eli Lilly Stock Slides
A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.
Don't expect much from Eli Lilly stock anymore, says Len Yaffee
Market expert Len Yaffee says it would be increasingly difficult for Eli Lilly (NYSE: LLY) to push higher from current levels – at least in the near-term. LLY shares have been standout performers in 2...
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
Eli Lilly's valuation may suggest that its market-beating days are behind it. However, the pharmaceutical giant still has significant momentum.
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.
Stock Split Watch: Is Eli Lilly Next?
Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company's portfolio of weight loss drugs, which has generated blockbuster revenue.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O...
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast cancer to be presented as a late-break...
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Josh Brown's ‘best stocks in the market': Health Care
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he's spotlighting Health Care in his "best stocks in the market." The Committee debates their health care s...
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare.
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...
Eli Lilly Stock Joins $1 Trillion Club: What Is Happening?
Eli Lilly's stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement sur...
Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound
Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ago...
2 Top Dividend Stocks for Growth-Oriented Investors
Alphabet's dividend is still new but looks secure given its fantastic business and growth prospects. Eli Lilly is increasing its top line at a dizzying pace and has a strong dividend growth record ove...
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up.
Eli Lilly Stock Value Tops $1 Trillion. Learn Why And If To Buy $LLY
Eli Lilly stock has risen 36% this year to reach a $1 trillion market capitalization – the first health-care company to reach this milestone, according to CNBC.
Eli Lilly: The Weight-Loss Leader With More Upside If Execution Holds
Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a new $1,165 price target.
When Investors Panic, I Buy Eli Lilly
Eli Lilly posts 54% revenue growth, raises guidance, and drives innovation in obesity and diabetes care. Read here for an analysis of LLY stock.
Eli Lilly and Company (LLY) Welcomes New Board Member
Eli Lilly and Company (LLY) Welcomes New Board Member
The Score: Nvidia, Constellation, Eli Lilly, Gap and More Stocks That Defined the Week
The Score is a weekly review of the biggest stock moves and the news that drove them.
US Stocks Rise Amid Fed Rate Cut Hints; LLY Hits Record High
US Stocks Rise Amid Fed Rate Cut Hints; LLY Hits Record High
Dow Jones Futures: Stocks Bounce, Still Battered; Nvidia, Apple, Eli Lilly In Focus
The stock market rebounded Friday on Fed rate cut hopes but suffered damaging weekly losses. Nvidia, Apple and Eli Lilly are in focus.
Eli Lilly Stock Closes Above $1 Trillion After Climbing $400 Billion in 3 Months
LLY Becomes Biggest Healthcare Company: Analyzing Stock's Stunning Rally
Eli Lilly (LLY) became the 10th U.S. company to tap $1 trillion in market cap and has outperformed most of its peers, particularly its biggest rival, Novo Nordisk (NVO). Rick Ducat shows just how mass...
Eli Lilly Becomes First Health-Care Company To Hit $1 Tln Market Value
(RTTNews) - Eli Lilly And Co. (LLY) became the talk on Friday by briefly becoming the first healthcare company in the world to hit a $1 trillion market value.